Mersana Therapeutics (NASDAQ:MRSN) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Mersana Therapeutics (NASDAQ:MRSN) issued its earnings results on Monday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05, Zacks reports. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million.

Mersana Therapeutics Stock Performance

Shares of MRSN stock opened at $0.48 on Tuesday. The company’s 50 day moving average is $0.84 and its 200 day moving average is $1.57. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 52-week low of $0.48 and a 52-week high of $6.28. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MRSN shares. William Blair initiated coverage on shares of Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price on shares of Mersana Therapeutics in a research note on Monday. Finally, Citigroup assumed coverage on shares of Mersana Therapeutics in a research note on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $4.25.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.